Plain-English translation of NCT05498116 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether , a medication that blocks inflammatory chemicals in the body, can help protect your kidneys and improve your heart health if you have type 1 diabetes and early kidney disease. Kidney damage is very common in people with type 1 diabetes and can eventually lead to serious problems, but this medication might slow that damage down. Researchers want to see if the treatment can reduce protein in your urine (a sign of kidney damage) and improve how well your kidneys and blood vessels work.
Kidney disease affects many people with type 1 diabetes and can eventually require dialysis or a transplant. Scientists believe that inflammation plays a major role in this damage, and this medication might help by reducing that inflammation.
You likely qualify if…
You likely don't qualify if…
You will take one capsule by mouth each day — either the active medication or a placebo (inactive pill), decided by chance. You will visit the research clinic for tests that measure your kidney function, heart health, and urine protein levels. The study will involve some blood tests and special imaging to check how well your blood vessels are working. You'll need to stay relatively inactive during the study (no more than 2 days per week of vigorous exercise), as intense activity can affect the measurements they're taking.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
United States